To order this detailed 720+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Inclusions
§
A detailed review of
the overall market landscape of gene therapies and gene editing therapies,
including information on phase of development (marketed, clinical, preclinical
and discovery) of pipeline candidates, key therapeutic areas (autoimmune
disorders, cardiovascular diseases, dermatological disorders, genetic
disorders, hematological disorders, immunological disorders, infectious
diseases, inflammatory disorders, liver diseases, metabolic disorders,
muscle-related diseases, nervous system disorders, oncological disorders,
ophthalmic diseases and others), target disease indication(s), type of vector
used, type of gene, therapeutic approach (gene augmentation, oncolytic viral
therapy and others), type of gene therapy (ex vivo and in vivo),
route of administration and special drug designation(s) awarded (if any).
§
A detailed review of
the players engaged in the development of gene therapies, along with
information on their year of establishment, company size, location of
headquarters, regional landscape and key players engaged in this domain.
§
An elaborate
discussion on the various types of viral and non-viral vectors, along with information
on design, manufacturing requirements, advantages and limitations of currently
available gene delivery vectors.
§
A discussion on the
regulatory landscape related to gene therapies across various geographies,
namely North America (the US and Canada), Europe and Asia-Pacific (Australia,
China, Hong Kong, Japan and South Korea), providing details related to the
various challenges associated with obtaining reimbursements for gene therapies.
§
Detailed profiles of
marketed and late stage (phase II/III and above) gene therapies, including
development timeline of the therapy, information on the current development
status, mechanism of action, affiliated technology, strength of patent
portfolio, dosage and manufacturing details, as well as details related to the
developer company.
§
An elaborate
discussion on the various commercialization strategies that can be adopted by
drug developers across different stages of therapy development, including prior
to drug launch, at / during drug launch and post-marketing.
§
A review of the
various emerging technologies and therapy development platforms that are being
used to design and manufacture gene therapies, featuring detailed profiles of
technologies that were / are being used for the development of four or more
products / product candidates.
§
An in-depth analysis
of various patents that have been filed / granted related to gene therapies and
gene editing therapies, since 2016. The analysis assesses several relevant
parameters associated with the patents, including type of patent (granted
patents, patent applications and others), publication year, regional
applicability, CPC symbols, emerging focus areas, leading industry players (in
terms of the number of patents filed / granted), and patent valuation.
§
A detailed analysis of
the various mergers and acquisitions that have taken place within this domain,
during the period 2015-2020, based on several relevant parameters, such as year
of agreement, type of deal, geographical location of the companies involved,
key value drivers, highest phase of development of the acquired company'
product and target therapeutic area.
§
An analysis of the
investments made at various stages of development in companies that are focused
in this area, between 2015-2020, including seed financing, venture capital
financing, IPOs, secondary offerings, debt financing, grants and other equity
offerings.
§
A detailed
geographical clinical trial analysis of completed, ongoing and planned studies
of numerous gene therapies, based on various relevant parameters, such as trial
registration year, trial status, trial phase, target therapeutic area,
geography, type of sponsor, prominent treatment sites and enrolled patient
population.
§
An analysis of the
various factors that are likely to influence the pricing of gene therapies,
featuring different models / approaches that may be adopted by manufacturers to
decide the prices of these therapies.
§
An analysis of the
big biopharma players engaged in this domain, featuring a heat map based on
parameters, such as number of gene therapies under development, funding
information, partnership activity and strength of patent portfolio.
§
An informed estimate
of the annual demand for gene therapies, taking into account the marketed
gene-based therapies and clinical studies evaluating gene therapies; the
analysis also takes into consideration various relevant parameters, such as
target patient population, dosing frequency and dose strength.
§
A case study on the
prevalent and emerging trends related to vector manufacturing, along with information
on companies offering contract services for manufacturing vectors. The study
also includes a detailed discussion on the manufacturing processes associated
with various types of vectors.
§
A discussion on the
various operating models adopted by gene therapy developers for supply chain
management, highlighting the stakeholders involved, factors affecting the
supply of therapeutic products and challenges encountered by developers across
the different stages of the gene therapy supply chain.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Therapeutic
approach
§
Gene augmentation
§
Oncolytic therapy
§
Immunotherapy
§
Others
§ Type
of gene therapy
§
Ex
vivo
§
In vivo
§
Type of vector used
§
Adeno associated virus
§
Adenovirus
§
Herpes simplex virus
§
Lentivirus
§
Plasmid DNA
§
Retrovirus
§
Others
§ Key
therapeutic areas
§ Autoimmune
disorders
§ Cardiovascular
diseases
§ Dermatological
disorders
§ Genetic
disorders
§ Hematological
disorders
§ Metabolic
disorders
§ Muscle-related
diseases
§ Oncological
disorders
§ Ophthalmic
diseases
§ Others
§ Route
of administration
§
Intraarticular
§
Intracerebellar
§
Intradermal
§
Intramuscular
§
Intratumoral
§
Intravenous
§
Intravesical
§
Intravitreal
§
Subretinal
§
Others
§ Key
geographical regions
§ North
America
§ Europe
§ Asia-Pacific
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/268/request-sample.html
Key Questions Answered
§
Who are the leading players engaged in the development of
gene therapies?
§
How many gene therapies are presently being evaluated
across different stages of development?
§
What are various diseases targeted by gene therapies?
§
What are the key technology platforms that are either
available, or being developed for gene therapy discovery and production?
§
What kind of vectors are commonly used for the delivery of
gene therapies?
§
What are the key regulatory guidelines governing the approval
of gene therapies, across various geographies?
§
What kind of pricing models and reimbursement strategies are
currently used by gene therapy developers?
§
What kind of contract services are offered related to gene
therapies? Who are the key players in this market?
§
What are the drivers of the M&A activity in this market?
§
What kind of investors have stake in the gene therapy market?
§
What kind of commercialization strategies are used by gene
therapy developers?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be
interested in the following titles:
1.
Viral Vectors,
Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition),
2021-2030
2.
Global T-Cell (CAR-T,
TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3.
Oncolytic
Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive
Insights, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
